Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DM97IN2)

Drug Name

Paltusotine Drug Info

Synonyms

Paltusotine; 2172870-89-0; Paltusotine [INN]; F2IBD1GMD3; CRN00808; CRN-00808; 3-[4-(4-aminopiperidin-1-yl)-3-(3,5-difluorophenyl)quinolin-6-yl]-2-hydroxybenzonitrile; 3-(4-(4-Aminopiperidin-1-yl)-3-(3,5-difluorophenyl)quinolin-6-yl)-2-hydroxybenzonitrile; Benzonitrile, 3-(4-(4-amino-1-piperidinyl)-3-(3,5-difluorophenyl)-6-quinolinyl)-2-hydroxy-; Benzonitrile, 3-[4-(4-amino-1-piperidinyl)-3-(3,5-difluorophenyl)-6-quinolinyl]-2-hydroxy-; UNII-F2IBD1GMD3; PALTUSOTINE [USAN]; SCHEMBL19769109; BDBM405588; GLXC-26596; PALTUSOTINE (CRN00808); US10351547, Compound 2-2; AKOS040759931; AT37182; MS-28323; HY-109155; CS-0116068; 3-[4-(4-Amino-1-piperidinyl)-3-(3,5-difluorophenyl)-6-quinolinyl]-2-hydroxybenzonitrile; IUD

Indication

Disease Entry	ICD 11	Status	REF
Acromegaly	5A60.0	Phase 3	[1]

Cross-matching ID

PubChem CID: 134168328
TTD Drug ID: DM97IN2

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Somatostatin receptor type 2 (SSTR2)	TTZ6T9E	SSR2_HUMAN	Agonist	[2]

------------------------------------------------------------------------------------

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule	Molecule Type	Gene Name	Liver	Colon	Kidney	Small Intestine
Somatostatin receptor type 2 (SSTR2)	DTT	SSTR2	4.703	4.931	5.624	5.184

Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease

Acromegaly

ICD Disease Classification

5A60.0

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Somatostatin receptor type 2 (SSTR2)	DTT	SSTR2	9.79E-07	-0.38	-0.65

Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1	ClinicalTrials.gov (NCT04837040) A Randomized, Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Paltusotine in Subjects With Acromegaly Treated With Long-acting Somatostatin Receptor Ligands (PATHFNDR-1). U.S.National Institutes of Health.
2	Paltusotine, a novel oral once-daily nonpeptide SST2 receptor agonist, suppresses GH and IGF-1 in healthy volunteers. Pituitary. 2022 Apr;25(2):328-339.